The FDA recently approved tazarotene (Avage, Allergan) 0.1% cream as an adjunctive agent for use in the palliation of fine facial wrinkling, facial mottled hyper- and hypopigmentation, and benign facial lentigines in patients who use comprehensive skin care and sunlight avoidance programs. Avage became available in pharmacies in January.
